Abclon: "Out-Licensed Gastric Cancer Drug Reconfirms Potential to Extend Progression-Free Survival"

Global Phase 2 Trial Results for HER2-Positive Gastric Cancer Released
"Median Progression-Free Survival Not Reached at 39-Month Follow-Up"

Abclon announced that its HER2-targeted gastric cancer treatment, HLX22 (development code name AC101), which was discovered and out-licensed by the company, has once again demonstrated the potential for prolonged progression-free survival (PFS) in long-term follow-up of the global Phase 2 clinical trial.

Jafar Azadani, Professor at MD Anderson Cancer Center in Texas, USA. Abclon

Abclon's global partner, Henlius, released an interview on May 21 with Jafar Azad, Professor at MD Anderson Cancer Center, Texas, USA, who serves as the global principal investigator (PI) for the HLX22 clinical trial.

According to the interview, the Phase 2 clinical trial of HLX22 has not yet reached the median progression-free survival (mPFS) even after approximately 39 months of long-term follow-up. According to the company, patients' progression-free survival continues to be extended to date.

HLX22 is an antibody therapy being developed as a first-line treatment for HER2-positive gastric cancer. It is being evaluated for its potential synergy in combination therapy, based on a mechanism that targets a different binding site than existing HER2-targeted therapies.

In the interview, Professor Azad stated, "HLX22 is presenting new treatment possibilities based on a mechanism differentiated from existing therapies," adding, "It has the potential to address unmet needs for patients with HER2-positive gastric cancer."

Currently, HLX22 is undergoing a global Phase 3 clinical trial. Abclon expects that, depending on future clinical progress, milestone and royalty revenues may be generated.

This content was produced with the assistance of AI translation services.